Flavor manufacturer Symrise has partnered with Shan Foods to intends to deliver taste solutions for food in Pakistan.
The collaboration will enable the companies to co-develop consumer-led concepts and taste solutions for high-growth categories such as culinary and snacks.
It will also advance taste, nutrition, and health food technology platforms in Pakistan.
According to Sammer Sultan, co-chairperson of Shan Foods, their partnership with Symrise reinforces their position as a brand that continuously explores new ideas and drives food innovation and taste development in Pakistan.
The companies will focus on developing, launching, and commercializing food products such as seasonings, bouillons, processed meat, snacks, and instant noodles.
Symrise’s president of food and beverage for Europe, Africa & Middle East, Walter Ribeiro, said the partnerships will help them further consolidate their foothold in the Middle East and Africa.


Office design isn’t keeping up with post-COVID work styles - here’s what workers really want
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance
The Beauty Beneath the Expressway: A Journey from Self to Service
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
AI is driving down the price of knowledge – universities have to rethink what they offer
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
U.S. Stock Futures Slip as Markets Brace for Big Tech Earnings and Key Data
Trump Announces U.S.–India Trade Deal Cutting Tariffs, Boosting Markets and Energy Ties
Gold and Asian Stocks Rebound as Market Volatility Eases and Global Sentiment Improves
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 



